SCHEMBL4537117

SCHEMBL4537117

CNC(CO)c1cccc(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 1/20 0.44
TDO2 P48775 1/20 0.44
SLC6A4 P31645 4/20 0.43
SLC6A2 P23975 3/20 0.43
ADRB2 P07550 1/20 0.41
ADRB1 P08588 1/20 0.41
ADRB3 P13945 1/20 0.41
ACP3 P15309 1/20 0.41
DCAF1 Q9Y4B6 1/20 0.41
TAAR1 Q96RJ0 1/20 0.41
AOC3 Q16853 1/20 0.41
SLC2A1 P11166 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
AURKA O14965 1/20 0.40
RPS6KB1 P23443 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14350620 1.00 IDO1 (0.44) IDO1TDO2SLC6A4SLC6A2ADRB2
SCHEMBL13076109 0.85 SLC6A4 (0.43) SLC6A4SLC6A2ADRB2ADRB1ADRB3
SCHEMBL14107607 0.85 IDO1 (0.46) IDO1TDO2SLC6A4SLC6A2ADRB2
SCHEMBL10959452 0.84 AURKA (0.43) SLC6A4SLC6A2DCAF1TAAR1AOC3
SCHEMBL27351455 0.82 ADRB2 (0.43) IDO1TDO2SLC6A4SLC6A2ADRB2
SCHEMBL14338095 0.82 ADRB2 (0.43) IDO1TDO2SLC6A4SLC6A2ADRB2
SCHEMBL14252613 0.82 ADRB2 (0.43) IDO1TDO2SLC6A4SLC6A2ADRB2
SCHEMBL13851783 0.82 CTSA (0.51) SLC6A4ACP3DCAF1ALDH1A1HPGD
SCHEMBL24453717 0.81 USP1 (0.43) SLC6A4SLC6A2ACP3AOC3ALDH1A1
SCHEMBL14262065 0.81 USP1 (0.43) SLC6A4SLC6A2ACP3AOC3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012064269-A1 COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES ASTRAZENECA AB (SE) 2012-05-18 WO disclosed
US-7345054-B2 Heterocyclic inhibitors of ERK2 and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-03-18 US disclosed